Aim 2

1. Cross-sectionally and longitudinally examining the impact of MCCs and medications on the biomarkers.

2. Determining whether the biomarkers predict cognitive decline beyond the risk posed by the MCCs.

3. Developing an algorithm to interpret the biomarkers given the presence of specific MCCs, age, and sex.

4. Testing the algorithm for diagnostic accuracy compared to CSF or amyloid and tau PET.

5. Delineating normal ranges for the blood biomarkers by age, sex, race/ethnicity, and MCCs.